Top in ID: COVID-19 antiviral, second US monkeypox case

Pfizer recently announced that it is requesting emergency use authorization for its COVID-19 antiviral Paxlovid and that it would expand access to the drug by allowing generic manufacturers to produce it in low- and middle-income countries.

The announcement was the top story in infectious disease last week.

Another top story was about the second travel-related monkeypox case in the United States this year, which was identified in a U.S. citizen traveling from Nigeria.

Read these and more top stories in infectious disease below:

Pfizer seeks EUA for Paxlovid, will allow generics of COVID-19 antiviral

Pfizer said Tuesday that it is seeking emergency use authorization from the FDA for its investigational COVID-19 pill and will allow generic drug makers to produce the novel antiviral for low- and middle-income countries. Read more.

CDC confirms second travel-related case of monkeypox in US this year

The CDC confirmed Wednesday that another traveler returning to the United States from Nigeria was diagnosed with monkeypox. Read more.

FDA authorizes messenger RNA COVID-19 boosters for all adults

Just 8 weeks after it authorized booster doses of the Pfizer-BioNTech COVID-19 vaccine for people at high risk for severe disease, the FDA on Friday announced that any adult is now eligible for an extra shot. Read more.

PWUD discharged to skilled nursing facilities often do not complete OPAT

Many people who use drugs who are sent to skilled nursing facilities for outpatient parenteral antibiotic therapy do not complete treatment, according to findings from a single-center study published in Open Forum Infectious Diseases. Read more.

IDSA, ASM outline role of SARS-CoV-2 sequencing in clinical settings

A joint consensus review from the Infectious Diseases Society of America and the American Society for Microbiology outlined the potential role and challenges of SARS-CoV-2 sequencing in clinical care. Read more.